Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis

详细信息    查看全文

• 作者：Madhur Nayan^a ; Nahid Punjani^b ; David N. Juurlink^c ; ^d ; Antonio Finelli^a ; Peter C. Austin^d ; ^e ; ^f ; Girish S. Kulkarni^a ; Elizabeth Uleryk^g ; Robert J. Hamilton^a ; ^{rob.hamilton@uhn.ca}
• 关键词：HMG-CoA reductase inhibitor ; Kidney neoplasms ; Nephrectomy ; Prognosis
• 刊名：Cancer Treatment Reviews
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：52
• 期：Complete
• 页码：105-116
• 全文大小：1318 K
• 卷排序：52

文摘

Studies on statin use and kidney cancer survival have had conflicting results. In this review, we pooled data from 12 studies involving 18,105 patients. No study was found to be at high risk of bias based on the Newcastle–Ottawa Scale. Statin use significantly reduced risks of cancer-specific and all-cause mortality. Statins may have a therapeutic role in improving kidney cancer survival.